PE20141944A1 - N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina - Google Patents

N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina

Info

Publication number
PE20141944A1
PE20141944A1 PE2014000009A PE2014000009A PE20141944A1 PE 20141944 A1 PE20141944 A1 PE 20141944A1 PE 2014000009 A PE2014000009 A PE 2014000009A PE 2014000009 A PE2014000009 A PE 2014000009A PE 20141944 A1 PE20141944 A1 PE 20141944A1
Authority
PE
Peru
Prior art keywords
methylacetidine
fluorobenzyltio
dihydroxibutan
iloxi
sulphonamide
Prior art date
Application number
PE2014000009A
Other languages
English (en)
Inventor
Stephen Connolly
Mark Richard Ebden
Thomas Langer
Alan Robert Steven
Craig Robert Stewart
Paula Margaret Tomlin
Iain Alastair Stewart Walters
Andrew John Williams
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20141944A1 publication Critical patent/PE20141944A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Abstract

SE REFERIE A UN COMPUESTO QUE ES UNA SULFONAMIDA PIRIMIDINA DE LA FORMULA (I). SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR QUIMIOCINA COMO EL ASMA, RINITIS ALERGICA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ENTRE OTROS
PE2014000009A 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina PE20141944A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161506737P 2011-07-12 2011-07-12

Publications (1)

Publication Number Publication Date
PE20141944A1 true PE20141944A1 (es) 2014-12-24

Family

ID=46513787

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014000009A PE20141944A1 (es) 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina
PE2018000520A PE20181069A1 (es) 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018000520A PE20181069A1 (es) 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina

Country Status (37)

Country Link
US (3) US8735413B2 (es)
EP (2) EP3255043B1 (es)
JP (2) JP6006308B2 (es)
KR (1) KR101946664B1 (es)
CN (1) CN103781781B (es)
AR (2) AR087168A1 (es)
AU (2) AU2012282316B2 (es)
BR (1) BR112014000636B1 (es)
CA (1) CA2841859C (es)
CL (1) CL2014000079A1 (es)
CO (1) CO6852072A2 (es)
CR (1) CR20140007A (es)
CU (2) CU24292B1 (es)
CY (1) CY1124329T1 (es)
DK (1) DK3255043T3 (es)
DO (1) DOP2013000308A (es)
EA (1) EA027821B1 (es)
EC (1) ECSP14013130A (es)
ES (1) ES2861927T3 (es)
HK (1) HK1245779A1 (es)
HR (1) HRP20210413T1 (es)
HU (1) HUE053703T2 (es)
IL (1) IL230398A (es)
LT (1) LT3255043T (es)
MX (2) MX353334B (es)
MY (1) MY180039A (es)
NI (1) NI201400002A (es)
PE (2) PE20141944A1 (es)
PL (1) PL3255043T3 (es)
PT (1) PT3255043T (es)
RS (1) RS61608B1 (es)
SG (1) SG10201605619XA (es)
SI (1) SI3255043T1 (es)
TW (2) TWI633098B (es)
UY (1) UY34191A (es)
WO (1) WO2013008002A1 (es)
ZA (1) ZA201401059B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548044C2 (ru) 2010-07-13 2015-04-10 Астразенека Аб Новые кристаллические формы n-[-2[[(2,3-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азетидин-сульфонамида
MY180039A (en) * 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
BR112018068393A2 (pt) * 2016-03-11 2019-01-15 Ardea Biosciences Inc inibidores de cxcr-2 para o tratamento de distúrbios de artropatia por cristais
TW201919599A (zh) * 2017-09-12 2019-06-01 美商亞德生化公司 用於治療病症之cxcr-2抑制劑
ES2963356T3 (es) * 2019-06-12 2024-03-26 Nouryon Chemicals Int Bv Método para aislar ácido carboxílico a partir de una corriente lateral acuosa

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FI981521A0 (fi) * 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
AU2001266233B2 (en) 2000-07-07 2006-06-29 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
CZ200331A3 (cs) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Deriváty kolchinolu jako inhibitory angiogeneze, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
RS53145B (en) 2004-08-28 2014-06-30 Astrazeneca Ab. PIRIMIDINE SULFONAMIDE DERIVATIVES AS CHEMOKIN RECEPTOR MODULATORS
JP5237115B2 (ja) * 2006-01-19 2013-07-17 オーキッド リサーチ ラボラトリーズ リミテッド 新規複素環類
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
KR20110031462A (ko) 2008-07-16 2011-03-28 아스트라제네카 아베 피리미딜 술폰아미드 유도체 및 케모카인 매개 질환의 치료를 위한 그의 용도
JP2011529027A (ja) 2008-07-25 2011-12-01 ビーエーエスエフ ソシエタス・ヨーロピア ３−アミノメチル−１−シクロヘキシルアミン、及びその製造方法
RU2548044C2 (ru) * 2010-07-13 2015-04-10 Астразенека Аб Новые кристаллические формы n-[-2[[(2,3-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азетидин-сульфонамида
MY180039A (en) * 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Also Published As

Publication number Publication date
MY180039A (en) 2020-11-20
NZ619001A (en) 2016-05-27
US20130040926A1 (en) 2013-02-14
MX2013015085A (es) 2014-01-24
JP6261666B2 (ja) 2018-01-17
BR112014000636A2 (pt) 2017-01-10
CN103781781B (zh) 2015-08-26
PL3255043T3 (pl) 2021-07-12
JP2014520838A (ja) 2014-08-25
EA201490077A1 (ru) 2014-10-30
AU2012282316A1 (en) 2013-05-02
CY1124329T1 (el) 2022-07-22
CR20140007A (es) 2014-05-14
RS61608B1 (sr) 2021-04-29
TW201825479A (zh) 2018-07-16
JP6006308B2 (ja) 2016-10-12
US9975881B2 (en) 2018-05-22
EP2731945A1 (en) 2014-05-21
CU20140004A7 (es) 2014-05-27
DK3255043T3 (da) 2021-03-29
TWI659026B (zh) 2019-05-11
EA027821B1 (ru) 2017-09-29
ECSP14013130A (es) 2014-02-28
US20140228339A1 (en) 2014-08-14
ES2861927T3 (es) 2021-10-06
US20160108023A1 (en) 2016-04-21
CA2841859A1 (en) 2013-01-17
BR112014000636B1 (pt) 2022-08-30
LT3255043T (lt) 2021-04-12
NI201400002A (es) 2016-02-16
AU2016244246B2 (en) 2017-11-23
AU2012282316B2 (en) 2016-07-14
PT3255043T (pt) 2021-03-29
HK1245779A1 (zh) 2018-08-31
US8735413B2 (en) 2014-05-27
UY34191A (es) 2013-02-28
NZ719176A (en) 2017-11-24
ZA201401059B (en) 2017-09-27
HRP20210413T1 (hr) 2021-05-14
SG10201605619XA (en) 2016-08-30
CN103781781A (zh) 2014-05-07
CU24292B1 (es) 2017-12-08
HUE053703T2 (hu) 2021-07-28
AU2016244246A1 (en) 2016-10-27
WO2013008002A1 (en) 2013-01-17
TW201311670A (zh) 2013-03-16
KR101946664B1 (ko) 2019-02-11
IL230398A (en) 2017-10-31
KR20140037915A (ko) 2014-03-27
CU20160083A7 (es) 2017-03-03
CA2841859C (en) 2021-03-09
PE20181069A1 (es) 2018-07-04
AR124688A2 (es) 2023-04-26
CO6852072A2 (es) 2014-01-30
CL2014000079A1 (es) 2014-06-27
AR087168A1 (es) 2014-02-26
MX342874B (es) 2016-10-17
JP2016190864A (ja) 2016-11-10
EP3255043A3 (en) 2018-04-18
TWI633098B (zh) 2018-08-21
EP3255043A2 (en) 2017-12-13
SI3255043T1 (sl) 2021-04-30
DOP2013000308A (es) 2014-02-28
EP3255043B1 (en) 2021-01-20
MX353334B (es) 2018-01-09
US9221782B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
PE20190511A1 (es) Piridinas sustituidas con heteroarilo y metodos de uso
PE20141944A1 (es) N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina
CL2016001947A1 (es) Compuestos derivados de dihidropirrolopiridina, inhibidores de ror-gamma (ror); composición farmacéutica; y uso en el tratamiento de asma, enfermedad pulmonar obstructiva crónica, artritis reumatoide, fibrosis quística, psoriasis, epilepsia, alzheimer, entre otras.
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
PE20170502A1 (es) ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
UY33735A (es) Compuestos antivirales
BR112015021888A2 (pt) inibidores de dna-ik
NI201300068A (es) Moduladores del receptor de glucagón
CU20110168A7 (es) Derivados de benzofuranilo
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
CL2012002570A1 (es) Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios.
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
AR088971A1 (es) INHIBIDOR DE a₁-PROTEINASA PARA DEMORAR EL COMIENZO O PROGRESION DE EXACERBACIONES PULMONARES
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
AR080527A1 (es) Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2
CO6741219A2 (es) Inhibidores de catepsina c
CO6612187A2 (es) Inhibidores de catepsina c
CR20120103A (es) Inhibidores de catepsina c
SV2010003730A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CU20100217A7 (es) Derivados de quinuclidina como antagonistas de receptores muscarínicos m3
CU20100070A7 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotrópicos (mglurs)

Legal Events

Date Code Title Description
FG Grant, registration